# Floto Review

> Floto Review is an independent publication covering Exchange listings, IPOs & going public. Focus: IPO pricing reviews from final prospectuses. Published by Independent Journal; sponsored by Adamson Brothers Corp. (see the About page). Articles are drafted from primary sources with AI assistance and reviewed under our editorial policy. Not investment advice.

## Usage
- AI crawlers and assistants may read and index this site.
- Quotation and citation are welcome with attribution to the publication and a link to the article URL.
- News articles are time-sensitive; check the publication date. Guides are evergreen and updated over time.

## Sections
- [Latest news](https://flotoreview.com/): newest articles first
- [Guides](https://flotoreview.com/guides/): evergreen explainers
- [Topics](https://flotoreview.com/topics/): topic index
- [Writers](https://flotoreview.com/authors/): bylines and beats
- [RSS feed](https://flotoreview.com/rss.xml)
- [Sitemap](https://flotoreview.com/sitemap-index.xml)

## Guides
- [IPO lock-up periods explained: who is bound and what happens at expiry](https://flotoreview.com/ipo-lock-up-periods-explained/): What an IPO lock-up period is, who must hold their shares, how long lock-ups usually last, and why the expiration date can matter for a newly public stock.
- [Reading a 424B4 final prospectus: a section-by-section guide](https://flotoreview.com/reading-a-424b4-final-prospectus/): What a 424B4 final prospectus is, when it is filed, and how to read its cover page, underwriting, dilution and use of proceeds sections, step by step.
- [How IPO pricing works: from price range to final prospectus](https://flotoreview.com/how-ipo-pricing-works/): How IPO pricing works: underwriters, the order book, the price range and the final 424B4 prospectus, explained in plain English for general readers today.

## Recent articles
- [Retension Pharmaceuticals Files 424B4 Prospectus for IPO](https://flotoreview.com/retension-pharmaceuticals-424b4-prospectus-ipo/) (2026-10-13): Retension Pharmaceuticals filed its final 424B4 prospectus with the SEC on Oct. 9, 2026. Here is what the filing signals and what to check in the pricing terms.
- [Capital Group wins Abu Dhabi FSRA license in Gulf finance push](https://flotoreview.com/capital-group-abu-dhabi-fsra-license-finance/) (2026-10-07): Capital Group, with $3.6 trillion in assets, says it has received an FSRA license in Abu Dhabi as it expands in the Middle East. What is known so far, and what to watch.
- [Cyient's AI Engineering Unit: A Signal for Tech Companies](https://flotoreview.com/cyient-intelligent-engineering-tech-companies/) (2026-10-06): Cyient has set up an Intelligent Engineering Solutions unit and launched CYiNGINE, a platform-led AI model for lifecycle engineering. Here is what is known so far.
- [Hovione's Tableting News vs. a SPAC 424B4 Prospectus](https://flotoreview.com/hovione-tableting-news-spac-424b4-prospectus/) (2026-10-05): Hovione's continuous tableting announcement landed in an IPO news feed, but it isn't a listing event. A SPAC's 424B4 prospectus filing is what to watch.
- [Bluerock Acquisition II IPO Pricing: $150 Million, Trust at $10.05](https://flotoreview.com/bluerock-acquisition-ii-ipo-pricing-trust-10-05/) (2026-09-29): Bluerock Acquisition Corp. II priced a $150 million SPAC IPO on Nasdaq that closed at $172.5 million, with a $10.05-a-unit trust and a 21-month deadline.
- [424B4 Prospectus: Black Hawk SPAC Merger Values Vesicor at $70M](https://flotoreview.com/black-hawk-vesicor-424b4-prospectus-spac-merger/) (2026-09-22): Black Hawk Acquisition Corp filed a 424B4 proxy and prospectus for its merger with biotech Vesicor Therapeutics at a $70 million equity value; vote set Oct. 13.
- [Electra Therapeutics IPO Pricing: $350 Million at $15 a Share](https://flotoreview.com/electra-therapeutics-ipo-pricing-review/) (2026-09-18): Electra Therapeutics priced 23.3 million shares at $15 in its September 2026 Nasdaq IPO. Our review of the 424B4 prospectus, pipeline, losses and cash.
- [Inflection Point VIII IPO Pricing: $287.5 Million on Nasdaq](https://flotoreview.com/inflection-point-viii-spac-ipo-pricing/) (2026-09-02): Inflection Point Acquisition Corp. VIII priced a SPAC IPO at $10 a unit on Nasdaq and, with the over-allotment exercised in full, raised $287.5 million.
- [NorthStrive Acquisition IPO Pricing: $100 Million, Nasdaq](https://flotoreview.com/northstrive-acquisition-ipo-pricing-trust/) (2026-08-20): NorthStrive Acquisition Corp I priced a $100 million SPAC IPO at $10 a unit on Nasdaq and put the full amount in trust, with a 12-month window plus extensions.
- [OceanLight Acquisition IPO Pricing: $100 Million on Nasdaq](https://flotoreview.com/oceanlight-acquisition-ipo-pricing-nasdaq/) (2026-08-12): OceanLight Acquisition Corp priced a $100 million SPAC IPO at $10 a unit on Nasdaq, with rights and warrants in each unit and a closing 8-K detailing the sale.
- [Jersey Mike's IPO Pricing: $23 a Share and a $1 Billion Offering](https://flotoreview.com/jersey-mikes-ipo-pricing-review/) (2026-07-31): Jersey Mike's Subs priced 43.5 million shares at $23 in its July 2026 NYSE IPO, a $1 billion deal. Our 424B4 review covers proceeds, debt and control.
- [Samos Energy SPAC IPO Pricing: $10 a Unit on the NYSE](https://flotoreview.com/samos-energy-spac-ipo-pricing-nyse/) (2026-07-15): Samos Energy Acquisition Corp priced its IPO at $10.00 a unit on the NYSE with Cantor as sole bookrunner, and an 8-K details trust funding and warrants.
- [Kardigan IPO Pricing: $400 Million Raised at $16 a Share](https://flotoreview.com/kardigan-ipo-pricing-424b4-review/) (2026-06-18): Cardiovascular biotech Kardigan priced 25 million shares at $16 in its June 2026 Nasdaq IPO. Our 424B4 review covers proceeds, pipeline, losses and cash.
- [Lincoln International IPO Pricing: $20 a Share in NYSE Debut](https://flotoreview.com/lincoln-international-ipo-pricing-review/) (2026-05-21): Lincoln International priced 21 million Class A shares at $20 in its May 2026 NYSE IPO. Our 424B4 review covers proceeds, debt paydown and partner control.
- [Cerebras IPO Pricing Review: $185 a Share in the 424B4 Prospectus](https://flotoreview.com/cerebras-ipo-pricing-424b4-review/) (2026-05-14): Cerebras Systems priced 30 million Class A shares at $185 in its May 2026 IPO, raising $5.55 billion on Nasdaq. Our review of the final 424B4 prospectus.

## Policies
- [About and ownership](https://flotoreview.com/about/)
- [Editorial policy](https://flotoreview.com/editorial-policy/)
- [Disclaimer](https://flotoreview.com/disclaimer/)
- [Privacy](https://flotoreview.com/privacy/)

## Contact
- Corrections and tips: editor@flotoreview.com